Loading News...
Back to Dashboard

Amgen Inc. (AMGN)

Real-time intraday values

Market Overview

From:
To:
AMGN Intraday
No data available
SymbolAMGN
IPO DateJun 17, 1983
CEOMr. Robert A. Bradway
Full Time Employees31.5k
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUnited States
ExchangeNasdaqGS
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Performance
PeriodReturn %Value Change
1 Day
-0.22%
-0.73 US$
5 Days
+0.34%
+1.15 US$
1 Month
-1.74%
-5.98 US$
6 Months
-1.74%
-6.00 US$

Analyzing Market with AI

Evaluating the last 30 days of history and fundamental metrics of AMGN...

Key Statistics
Market Cap
183.12B
P/E Ratio
23.58
Div Yield
297.00%
52W High
$391.29
52W Low
$267.83

Analyst Consensus

CONSENSUSBuy
BULLISH1440.0%
NEUTRAL1851.4%
BEARISH38.6%

52W Analyst Price Targets

Min Target
$200.00
Max Target
$427.00
Current$338.57
Avg Target$352.23

Analyst Recommendations

Precio Objetivo:$352.23($200.00 - $427.00)
FirmRatingTarget PriceUpside PotentialDate
Piper SandlerOverweight$427.00+26.12%5/14/2026
GuggenheimNeutral$340.00+0.42%5/4/2026
Truist SecuritiesHold$327.00-3.42%5/1/2026
Canaccord GenuityHold$366.00+8.10%4/21/2026
UBSBuy$400.00+18.14%4/13/2026
Morgan StanleyEqual-Weight$326.00-3.71%4/10/2026
GuggenheimNeutral$351.00+3.67%4/9/2026
Cantor FitzgeraldNeutral$350.00+3.38%4/8/2026
JefferiesHold$350.00+3.38%3/10/2026
BarclaysEqual-Weight$350.00+3.38%2/20/2026
Community Thoughts

Share your analysis and sentiment on AMGN

Join the community to share your analysis